Tengjun Biotechnology Corp. Deferred Revenue, Additions
Tengjun Biotechnology Corp. reported Deferred Revenue, Additions of $0 for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-15.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueAdditions · last filed 2023-08-15
- Tengjun Biotechnology Corp. deferred revenue, additions for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Tengjun Biotechnology Corp. deferred revenue, additions for the quarter ending 2023-03-31 was $8.52M, a 98.80% increase year-over-year.
- Tengjun Biotechnology Corp. deferred revenue, additions for the quarter ending 2022-12-31 was $58.14M.
- Tengjun Biotechnology Corp. deferred revenue, additions for the quarter ending 2022-09-30 was $36.42M.
- Tengjun Biotechnology Corp. deferred revenue, additions for fiscal 2022 was $150.14M.
| Period end | Deferred Revenue, Additions 3 month | Deferred Revenue, Additions 6 month | Deferred Revenue, Additions 9 month | Deferred Revenue, Additions 12 month |
|---|---|---|---|---|
| 2023-06-30 | $0.00 10-Q · filed 2023-08-15 | $8.52M 10-Q · filed 2023-08-15 | $66.66M derived: sum of 3 quarters · filed 2023-08-15 | $103.08M derived: sum of 4 quarters · filed 2023-08-15 |
| 2023-03-31 | $8.52M 10-Q · filed 2023-05-15 | $66.66M derived: sum of 2 quarters · filed 2023-05-15 | $103.08M derived: sum of 3 quarters · filed 2023-05-15 | $154.37M derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | $58.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $94.56M derived: sum of 2 quarters · filed 2023-04-17 | $145.85M derived: sum of 3 quarters · filed 2023-04-17 | $150.14M 10-K · filed 2023-04-17 |
| 2022-09-30 | $36.42M 10-Q · filed 2022-11-14 | $87.71M derived: sum of 2 quarters · filed 2022-11-14 | $91.99M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $51.29M 10-Q/A · filed 2022-09-16 | $55.57M 10-Q/A · filed 2022-09-16 | ||
| 2022-03-31 | $4.28M derived: 10-K 12 month − 3 quarters · filed 2023-04-17 |